Skip to main content
SpringerLink
Log in

Treatments for Benign Conditions of the Prostate Gland

  • Chapter
Interventional Urology

  • 1368 Accesses

Abstract

Histologically, the prostate is comprised of a network of branched tubuloalveolar glands that are surrounded by a richly innervated, well-vascularized fibromuscular stroma. Benign prostatic hyperplasia (BPH) is often referred to as the most common benign neoplasm in the aging male. It is a distinct histopathologic entity that is characterized by cellular proliferation of both components of the prostate: the glandular and stromal elements. From a clinical standpoint, this may be associated with age-dependent, bothersome, and progressive voiding symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McNeal JE. Pathology of benign prostatic hyperplasia: insight into etiology. Urol Clin N Am. 1990;17:477–86.

    CAS  Google Scholar 

  2. Lee C, Kozlowski J, Grayhack K. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate. 1997;31:131–8.

    Article  CAS  PubMed  Google Scholar 

  3. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America Project: benign prostatic hyperplasia. J Urol. 2005;173:1256–61.

    Article  PubMed  Google Scholar 

  4. Abrams P. New words for old: lower urinary tract symptoms for "prostatism". BMJ. 1994;308(6934):929–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Abrams P. LUTS, BPH, BPE, BPO: a plea for the logical use of correct terms. Rev Urol. 1999;1:65.

    PubMed Central  CAS  PubMed  Google Scholar 

  6. McVary KT, Roehrborn CG, et al. American Urological Association Guideline: management of benign prostatic hyperplasia (BPH), revised 2010. J Urol. 2011;185(5):1793–803

    Google Scholar 

  7. Reynard J. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol. 2004;14:13.

    Article  PubMed  Google Scholar 

  8. Abrams P, Cardozo L, et al. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology. 2003;61:37–49.

    Article  PubMed  Google Scholar 

  9. Kupelian V, Wei JT, O’Leary MP, Kuseck JQ, Litman HJ, Link CL, McKinlay JB. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample. Arch Intern Med. 2006;166:2381–7.

    Article  PubMed  Google Scholar 

  10. Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, Chapple CR, Kaplan S, Tubaro A, Aiyer LP, Wein AJ. The prevalence of lower urinary tract symptoms (LUTS) in the USA, The UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104:352–60.

    Article  PubMed  Google Scholar 

  11. Barry M, Fowler Jr F, O’Leary M, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549.

    CAS  PubMed  Google Scholar 

  12. Barry M, Fowler Jr F, O’Leary M, et al. Measurement Committee of the American Urological Association. Med Care. 1995;22:AS145.

    Google Scholar 

  13. Franks LM. Benin nodular hyperplasia of the prostate: a review. Ann R Coll Surg Engl (Lond). 1954;14:92–106.

    Google Scholar 

  14. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9.

    CAS  PubMed  Google Scholar 

  15. Oesterling JE, Jacobsen SJ, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA. 1993;270:860–4.

    Article  CAS  PubMed  Google Scholar 

  16. Roehrborn CG, Fuh V, et al. The relationship between total and free PSA, prostate volume and age in men age 40–60 with no clinical diagnosis of benign prostatic hyperplasia necessitating therapy. J Urol. 2000;163(Suppl):252.

    Google Scholar 

  17. Chute CG, Panser LA, Girman CJ, Oesterling JE, Gues HA, Jacobsen SJ, Lieber MM. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150:85–9.

    CAS  PubMed  Google Scholar 

  18. Wei JT, Schottenfeld D, Cooper K, Taylor JM, Faerber GJ, Velarde MA, Bree R, Montie JE, Cooney KA. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate, and bothersomeness. J Urol. 2001;165:1521–5.

    Article  CAS  PubMed  Google Scholar 

  19. McConnell JD, Roehrborn CG, Bautisa O, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–98.

    Article  CAS  PubMed  Google Scholar 

  20. Filson CP, Wei JT, Hollingsworth JM. Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2013;82:1386–93.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol. 2008;10:14–25.

    PubMed Central  PubMed  Google Scholar 

  22. Verhamme KMC, Dielman JP, Bleumink GS, Bosch JLHR, Stricker BHC, Sturkenboom MCJM. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUT suggestive of benign prostatic hyperplasia: the Triumph Project. Eur Urol. 2003;44:539–45.

    Article  CAS  PubMed  Google Scholar 

  23. Malaeb BS, Yu X, McBean AM, Elliot SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000–2008). Urology. 2012;79(5):1111–6.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’Dow J, Nordling J, de la Rosette JJ. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118–40.

    Article  PubMed  Google Scholar 

  25. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC. Transurethral prostatectomy: immediate and postoperative complications, a cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 1989;141:243–7.

    CAS  PubMed  Google Scholar 

  26. Doll HA, Black NA, McPherson K, Flood AB, Williams GB, Smith JC. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol. 1992;147:1566–73.

    CAS  PubMed  Google Scholar 

  27. Horninger W, Unterlechner H, Strasser H, Bartsch G. Transurethral prostatectomy: mortality and morbidity. Prostate. 1996;28:195–200.

    Article  CAS  PubMed  Google Scholar 

  28. Uchida T, Ohori M, Soh S, Sato T, Iwamura M, Ao T, Koshiba K. Factors influencing morbidity in patients undergoing transurethral resection of the prostate. Urology. 1999;53:98–104.

    Article  CAS  PubMed  Google Scholar 

  29. Berger AP, Wirtenberger W, Bektic J, Steiner H, Spranger R, Bartsch G. Safer transurethral resection of the prostate: coagulating intermittent cutting reduces hemostatic complications. J Urol. 2004;171:289–91.

    Article  PubMed  Google Scholar 

  30. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, Lack N, Stief CG. Morbidity, mortality, and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180:246–9.

    Article  PubMed  Google Scholar 

  31. Mamoulakis C, Efthimlou I, Kazoulis S, Christoulakis I, Sofras F. The modified Clavien classification system: a standard platform for reporting complications in transurethral resection of the prostate. World J Urol. 2011;29:205–10.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Madersbacher S, Lackner J, Brossner C, Rohlich M, Stancik I, Willinger M, Schatzl G. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide long-term analysis of 23,123 cases. Eur Urol. 2005;47:499–504.

    Article  PubMed  Google Scholar 

  33. Varkarakis J, Bartsch G, Horninger W. Long-term morbidity and mortality of transurethral prostatectomy: a 10-year follow-up. Prostate. 2004;58:248–51.

    Article  PubMed  Google Scholar 

  34. Rassweiller J, Schulze M, Stock C, Teber D, de La Rosette J. Bipolar transurethral resection of the prostate- technical modifications and early clinical experience. Minim Invasive Ther Allied Technol. 2007;16:11–21.

    Article  Google Scholar 

  35. Geavlete B, Stanescu F, Iacoboaie C, Geavlete P. Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases- a medium term, prospective, randomized comparison. BJU Int. 2013;111:793–803.

    Article  CAS  PubMed  Google Scholar 

  36. Cornu J-N, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, McVary K, Novara G, Woo H, Madersbacher S. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67(6):1066–96.

    Article  PubMed  Google Scholar 

  37. Autorino R, Damiano R, DiLorenzo G, Quarto G, Persona S, D’Armiento M, DeSio M. Four year outcome of a prospective randomized trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Eur Urol. 2009;55:922–31.

    Article  PubMed  Google Scholar 

  38. Chen Q, Zhang L, Fan QL, Zhou J, Peng YB, Wang Z. Bipolar transurethral resection in saline vs traditional monopolar resection of the prostate: results of a randomized trial with a 2-year follow-up. BJU Int. 2010;106:1339–43.

    Article  PubMed  Google Scholar 

  39. Geavelete B, Georgescu D, Multescu R, Stanescu F, Jecu M, Geavlete P. Bipolar plasma vaporization vs monopolar and bipolar TURP- a prospective, randomized, long-term comparison. Urology. 2011;78:930–6.

    Article  Google Scholar 

  40. Mamoulakis C, Schulze M, Skolarikos A, Alivizatos G, Scarpa RM, Rassweiler JJ, de la Rosette JJMCH, Scaffone CM. Midterm results from an international multicentre randomized controlled trial comparing bipolar with monopolar transurethral resection of the prostate. Eur Urol. 2013;63:667–76.

    Article  PubMed  Google Scholar 

  41. Komura K, Inamoto T, Takai T, Uchimoto T, Saito K, Tanda N, Minami K, Uehara H, Takahara K, Hirano H, Nomi H, Kiyama S, Watsuji T, Azuma H. Could transurethral resection of the prostate using the TURis system take over conventional monopolar transurethral resection of the prostate? A randomized controlled trial and midterm results. Urology. 2014;84:405–11.

    Article  PubMed  Google Scholar 

  42. Te AE. The development of laser prostatectomy. BJU Int. 2004;93:262–5.

    Article  CAS  PubMed  Google Scholar 

  43. Teichmann H-O, Herrmann TR, Bach T. Technical aspects of lasers in urology. World J Urol. 2007;25:221–5.

    Article  PubMed  Google Scholar 

  44. Marks AJ, Teichman JMH. Lasers in clinical urology: state of the art and new horizons. World J Urol. 2007;25:227–33.

    Article  PubMed  Google Scholar 

  45. Hermann TRW, Liatsikos EN, Nagele U, Traxer O, Merseburger AS. EAU guidelines on laser technologies. Eur Urol. 2012;61:783–95.

    Article  Google Scholar 

  46. Reich O, Bachmann A, Schneede P, Zaak D, Sulser T, Hofstetter A. Experimental comparison of high power (80W) potassium titanyl phosphate laser vaporization and transurethral resection of the prostate. J Urol. 2004;171:2502–4.

    Article  PubMed  Google Scholar 

  47. Bachmann A, Schurch L, Ruszat R, Wyler SF, Seifert H-H, Muller A, Lehmann K, Sulser T. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP); a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol. 2005;48:965–72.

    Article  PubMed  Google Scholar 

  48. Sulser T, Reich O, Wyler S, Ruszat R, Casella R, Hofstetter A, Bachmann A. Photoselective KTP laser vaporization of the prostate: first experiences with 65 procedures. J Endourol. 2004;18:976–81.

    Article  PubMed  Google Scholar 

  49. Malek RS, Barrett DM, Kuntzman RS. High power potassium titanyl phosphate (KTP/532) laser vaporization prostatectomy: 24 hours later. Urology. 1998;51:254–6.

    Article  CAS  PubMed  Google Scholar 

  50. Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA, Malek RS. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12 month results from the first United States multicenter prospective trial. J Urol. 2004;172:1404–8.

    Article  PubMed  Google Scholar 

  51. Bouchier-Hayes DM, Van Appledorn S, Bugeja P, Crowe H, Challacombe B, Costello AJ. A randomized trial of photoselective vaporization of the prostate using the 80-W potassium-titanyl-phosphate laser vs transurethral prostatectomy, with a 1-year follow-up. BJU Int. 2010;105:964–9.

    Article  PubMed  Google Scholar 

  52. Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70ml: a short-term prospective randomized trial. Urology. 2008;71:247–51.

    Article  PubMed  Google Scholar 

  53. Skolarikos A, Papachristou C, Athanasiadis G, Chalikopoulos D, Deliveliotis C, Alivaizatos G. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80cc. J Endourol. 2008;22:2333–40.

    Article  PubMed  Google Scholar 

  54. Lukacs B, Loeffler J, Bruyere F, Blanchet P, Gelet A, Coloby P, De la Taille A, Lemaire P, Baron J-C, Cornu J-N, Aout M, Rousseau H, Vicaut E. Photoselective vaporization of the prostate with GreenLight 120-W laser compared with monopolar transurethral resection of the prostate: a multicenter randomized controlled trial. Eur Urol. 2012;61:1165–73.

    Article  PubMed  Google Scholar 

  55. Bachman A, Tubaro A, Barber N, d’Ancona F, Muir G, et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6 month safety and efficacy results of a European multicentre randomized trail – the Goliath Study. Eur Urol. 2014;65:931–42.

    Article  Google Scholar 

  56. Pfitzenmaier J, Gilfrich C, Pritsch M, et al. Vaporization of prostates of > or = 80ml using a potassium-titanyl-phosphate laser: mid-term results and comparison with prostates < 80ml. BJU Int. 2008;102:322–7.

    Article  CAS  PubMed  Google Scholar 

  57. Al-Ansari A, Younes N, Sampige VP, et al. Greenlight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow –up. Eur Urol. 2010;58:349–55.

    Article  PubMed  Google Scholar 

  58. Tasci AI, Tugcu V, Sahin S, Zorluoglu F. Rapid communication photoselective vaporization of the prostate versus transurethral resection of the prostate for the large prostate: a prospective nonrandomized bicenter trial with 2-year follow- up. J Endourol. 2008;22:347–53.

    Article  PubMed  Google Scholar 

  59. Thangasamy IA, Chalasani V, Bachmann A, Woo HH. Photoselective vaporisation of the prostate using 80W and 120W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012. Eur Urol. 2012;62:315–23.

    Article  PubMed  Google Scholar 

  60. Gilling PJ, Fraundorfer MR. Holmium laser prostatectomy: a technique in evolution. Curr Opin Urol. 1998;8:11–5.

    Article  CAS  PubMed  Google Scholar 

  61. Motet N, Anidjar M, Bourdon O, et al. Randomized comparison of transurethral electroresection and holmium:YAG laser vaporization for symptomatic benign prostatic hyperplasia. J Endourol. 1999;13:127–30.

    Article  Google Scholar 

  62. Gilling PJ, Kennett KM, Das AK, Thomson D, Fraundorfer MR. Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation: an update on the early clinical experience. J Endourol. 1998;12:457–9.

    Article  CAS  PubMed  Google Scholar 

  63. Tan AH, Gilling PJ. Holmium laser prostatectomy: current techniques. Urology. 2002;60:152–6.

    Article  PubMed  Google Scholar 

  64. Gilling P, Mackey M, Cresswell M, et al. Holmium laser versus transurethral resection of the prostate: a randomized prospective trial with 1-year follow up. J Urol. 1999;162:1640–4.

    Article  CAS  PubMed  Google Scholar 

  65. Kuntz RM. Laser treatment of benign prostatic hyperplasia. World J Urol. 2007;25:241–7.

    Article  PubMed  Google Scholar 

  66. Tan AHH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40–200 grams). J Urol. 2003;170:1270–4.

    Article  CAS  PubMed  Google Scholar 

  67. Lerner LB, Tyson MD. Holmium laser applications of the prostate. Urol Clin North Am. 2009;36:485–95.

    Article  PubMed  Google Scholar 

  68. KuntzRM AS, Lehrich K, Fayad A. Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients. J Urol. 2004;172:1012–6.

    Article  Google Scholar 

  69. Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni M, Vanlenti S, Vavassori I, Rigatti P. Holmium laser enucleation versus transurethral resection of the prostate: results form a 2-center, prospective randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol. 2004;172(5):1926–9.

    Article  PubMed  Google Scholar 

  70. Gupta N, Sivaramakrishna Kumar R, Dogra PN, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40g. BJU Int. 2006;97:85–9.

    Article  PubMed  Google Scholar 

  71. Wilson LC, Gilling PJ, Williams A, Kennett KM, Frampton CM, Westenberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. Eur Urol. 2006;50(3):569–73.

    Article  PubMed  Google Scholar 

  72. Sun N, Fu Y, Tian T, Gao J, Wang Y, et al. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a randomized clinical trial. Int Urol Nephrol. 2014;46:1277–82.

    Article  PubMed  Google Scholar 

  73. Ahyai SA, Lehrich K, Kuntz RM. Holmium laser enucleation versus transurethral resection of the prostate: 3 year follow up results of a randomized clinical trial. Eur Urol. 2007;52:1456–63.

    Article  PubMed  Google Scholar 

  74. Naspro R, Suardi N, Salonia A, et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70g: 24 month follow- up. Eur Urol. 2006;50:563–8.

    Article  PubMed  Google Scholar 

  75. Kuntz RM, Lehrich K. Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100g: a randomized prospective trail of 120 patients. J Urol. 2002;168:1465–9.

    Article  PubMed  Google Scholar 

  76. Gilling PJ, Aho TF, Frampton CM, King CJ, Fraundorfer MR. Holmium laser enucleation of the prostate: results at 6 years. Eur Urol. 2008;53:744–9.

    Article  PubMed  Google Scholar 

  77. Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100g: 5 year follow up results of a randomized clinical trial. Eur Urol. 2008;53:160–8.

    Article  PubMed  Google Scholar 

  78. Xia S-J, Zhuo J, Sun X-W, Han B-M, Shao Y, Zhang Y-N. Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol. 2008;53:382–90.

    Article  PubMed  Google Scholar 

  79. Fu WJ, Zhang X, Yang Y, et al. Comparison of 2 micron continuous wave laser vaporesection of the prostate and transurethral resection of the prostate: a prospective, nonrandomized trial with 1-year follow up. Urology. 2010;75:194–9.

    Article  PubMed  Google Scholar 

  80. Shao Q, Zhang FB, Shang DH, Tian Y. Comparison of holmium and thulium laser in transurethral enucleation of the prostate. Zhonghua Nan Ke Xue. 2009;15:346–9 (in Chinese).

    PubMed  Google Scholar 

  81. Bolmsjo M, Wagrell L, Hallin A, Eliasson T, Erlandsson BE, Mattiasson A. The heat is on–but how? A comparison of TUMT devices. Br J Urol. 1996;78(4):564–72.

    Article  CAS  PubMed  Google Scholar 

  82. Hoffman RM, Monga M, Elliott SP, Macdonald R, Langsjoen J, Tacklind J, Wilt TJ. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;(9):CD004135. doi:10.1002/14651858.CD004135.pub3.

  83. Naslund MJ. Transurethral needle ablation of the prostate. Urology. 1997;50(2):167–72. doi:10.1016/S0090-4295(97)00277-X.

    Article  CAS  PubMed  Google Scholar 

  84. Bouza C, Lopez T, Magro A, Navalpotro L, Amate JM. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol. 2006;6:14. doi:10.1186/1471-2490-6-14.

    Article  PubMed Central  PubMed  Google Scholar 

  85. Campo B, Bergamaschi F, Corrada P, Ordesi G. Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation. Urology. 1997;49(6):847–50.

    Article  CAS  PubMed  Google Scholar 

  86. Steele GS, Sleep DJ. Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followup. J Urol. 1997;158(5):1834–8.

    Article  CAS  PubMed  Google Scholar 

  87. Murai M, Tachibana M, Miki M, Shiozawa H, Hirao Y, Okajima E. Transurethral needle ablation of the prostate: an initial Japanese clinical trial. Int J Urol. 2001;8(3):99–105.

    Article  CAS  PubMed  Google Scholar 

  88. Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol. 2003;44(1):89–93.

    Article  PubMed  Google Scholar 

  89. Larcher A, Broglia L, Lughezzani G, Mistretta F, Abrate A, Lista G, Fossati N, et al. Urethral lift for benign prostatic hyperplasia: a comprehensive review of the literature. Curr Urol Rep. 2013;14:620–7.

    Article  PubMed  Google Scholar 

  90. McNicholas TA, Woo HH, Chin PT, Bolton D, Arjona MF, et al. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol. 2013;64:292–9.

    Article  PubMed  Google Scholar 

  91. Roerhborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: The L.I.F.T. Study. J Urol. 2013;190:2161–7.

    Article  Google Scholar 

  92. Woo HH, Bolton DM, Laborde E, Jack G, Chin PT, Rashid P, Thavaseelan J, McVary KT. Preservation of sexual function with the prostatic urethral lift; a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9:568–75.

    Article  PubMed  Google Scholar 

  93. Granados EA, Riley G, Salvador J, Vincente J. Prostatic abscess: diagnosis and treatment. J Urol. 1992;148(1):80–2.

    CAS  PubMed  Google Scholar 

  94. Collado A, Palou J, Garcia-Penit J, Salvador J, de la Torre P, Vicente J. Ultrasound-guided needle aspiration in prostatic abscess. Urology. 1999;53(3):548–52.

    Article  CAS  PubMed  Google Scholar 

  95. Vyas JB, Ganpule SA, Ganpule AP, Sabnis RB, Desai MR. Transrectal ultrasound-guided aspiration in the management of prostatic abscess: a single-center experience. Indian J Radiol Imaging. 2013;23(3):253–7.

    Article  PubMed Central  PubMed  Google Scholar 

  96. Jang K, Lee DH, Lee SH, Chung BH. Treatment of prostatic abscess: case collection and comparison of treatment methods. Korean J Urol. 2012;53(12):860–4.

    Article  PubMed Central  PubMed  Google Scholar 

  97. Bachor R, Gottfried HW, Hautmann R. Minimal invasive therapy of prostatic abscess by transrectal ultrasound-guided perineal drainage. Eur Urol. 1995;28(4):320–4.

    CAS  PubMed  Google Scholar 

  98. Trauzzi SJ, Kay CJ, Kaufman DG, Lowe FC. Management of prostatic abscess in patients with human immunodeficiency syndrome. Urology. 1994;43(5):629–33.

    Article  CAS  PubMed  Google Scholar 

  99. Jacobsen JD, Kvist E. Prostatic abscess. A review of literature and a presentation of 5 cases. Scand J Urol Nephrol. 1993;27(2):281–4.

    Article  CAS  PubMed  Google Scholar 

  100. Barozzi L, Pavlica P, Menchi I, De Matteis M, Canepari M. Prostatic abscess: diagnosis and treatment. AJR Am J Roentgenol. 1998;170(3):753–7.

    Article  CAS  PubMed  Google Scholar 

  101. Varkarakis J, Sebe P, Pinggera GM, Bartsch G, Strasser H. Three-dimensional ultrasound guidance for percutaneous drainage of prostatic abscesses. Urology. 2004;63(6):1017–20; discussion 20.

    Article  PubMed  Google Scholar 

  102. Lim JW, Ko YT, Lee DH, Park SJ, Oh JH, Yoon Y, et al. Treatment of prostatic abscess: value of transrectal ultrasonographically guided needle aspiration. J Ultrasound Med. 2000;19(9):609–17.

    CAS  PubMed  Google Scholar 

  103. Coppens L, Bonnet P, Andrianne R, de Leval J. Adult mullerian duct or utricle cyst: clinical significance and therapeutic management of 65 cases. J Urol. 2002;167(4):1740–4.

    Article  PubMed  Google Scholar 

  104. Moukaddam HA, Haddad MC, El-Sayyed K, Wazzan W. Diagnosis and treatment of midline prostatic cysts. Clin Imaging. 2003;27(1):44–6.

    Article  PubMed  Google Scholar 

  105. Kim ED, Onel E, Honig SC, Lipschultz LI. The prevalence of cystic abnormalities of the prostate involving the ejaculatory ducts as detected by transrectal ultrasound. Int Urol Nephrol. 1997;29(6):647–52.

    Article  CAS  PubMed  Google Scholar 

  106. Halpern EJ, Hirsch IH. Sonographically guided transurethral laser incision of a Mullerian duct cyst for treatment of ejaculatory duct obstruction. AJR Am J Roentgenol. 2000;175(3):777.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Miami Health System, Miami, FL, USA

    Bruce R. Kava MD

  2. Department of Urology, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Jayadev R. Mettu MBBS

  3. Department of Radiology, Jackson Memorial Hospital, University of Miami Hospital, Miami, FL, USA

    Shivank Bhatia MD

  4. Department of Radiology, University of Miami Miller School of Medicine, Miami, FL, USA

    Prasoon P. Mohan MD

  5. Department of Urology, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA

    Gopal H. Badlani MD

Authors
  1. Bruce R. Kava MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jayadev R. Mettu MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shivank Bhatia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prasoon P. Mohan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gopal H. Badlani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gopal H. Badlani MD .

Editor information

Editors and Affiliations

  1. Focal Therapy and Interventional Urologic Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

    Ardeshir R. Rastinehad

  2. Department of Radiology, Hofstra North Shore LIJ School of Medici Department of Radiology, New Hyde Park, New York, USA

    David N. Siegel

  3. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    Peter A. Pinto

  4. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    Bradford J. Wood

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Kava, B.R., Mettu, J.R., Bhatia, S., Mohan, P.P., Badlani, G.H. (2016). Treatments for Benign Conditions of the Prostate Gland. In: Rastinehad, A., Siegel, D., Pinto, P., Wood, B. (eds) Interventional Urology. Springer, Cham. https://doi.org/10.1007/978-3-319-23464-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23464-9_16

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-23463-2

  • Online ISBN: 978-3-319-23464-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation